{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:23:12Z","timestamp":1770337392212,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"9-10","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1007\/bf03040906","type":"journal-article","created":{"date-parts":[[2009,5,13]],"date-time":"2009-05-13T04:57:52Z","timestamp":1242190672000},"page":"334-338","source":"Crossref","is-referenced-by-count":27,"title":["Refractory Wegener\u2019s granulomatosis responds to tumor necrosis factor blockade","TNF-Blockade bei therapierefrakt\u00e4rem Morbus Wegener"],"prefix":"10.1007","volume":"116","author":[{"given":"Julia","family":"Kleinert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"K\u00f6stler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"H\u00f6rl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gere","family":"Sunder-Plassmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afschin","family":"Soleiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF03040906_CR1","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1182\/blood.V75.11.2263.2263","volume":"75","author":"JC Jennette","year":"1990","unstructured":"Jennette JC, Hoidal JR, Falk RJ (1990) Specificity of antineutrophil cytoplasmic antiobodies for proteinase 3. Blood 75: 2263\u20132264","journal-title":"Blood"},{"key":"BF03040906_CR2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/00005792-197311000-00002","volume":"52","author":"AS Fauci","year":"1973","unstructured":"Fauci AS, Wolff SM (1973) Wegener\u2019s granulomatosis: Studies in eighteen patients and a review of the literature. Medicine 52: 535\u2013561","journal-title":"Medicine"},{"key":"BF03040906_CR3","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/thx.54.7.629","volume":"54","author":"CA Langford","year":"1999","unstructured":"Langford CA, Hoffman GS (1999) Wegener\u2019s granulomatosis. Thorax 54: 629\u2013637","journal-title":"Thorax"},{"key":"BF03040906_CR4","first-page":"930","volume":"113","author":"A Kaser","year":"2001","unstructured":"Kaser A, Mairinger T, Vogel W, Tilg H (2001) Infliximab in severe steroid-refractory ulcerative colitis: a pilot study. Wien Klin Wochenschr 113: 930\u2013933","journal-title":"Wien Klin Wochenschr"},{"key":"BF03040906_CR5","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.4049\/jimmunol.160.7.3602","volume":"160","author":"BR Ludviksson","year":"1998","unstructured":"Ludviksson BR, Sneller MC, Chua KS, Talar-Williams C, Langford CA, Ehrhardt RO, et al (1998) Active Wegener\u2019s granulomatosis is associated with HLA-DR+CD4+T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10. J Immun 160: 3602\u20133609","journal-title":"J Immun"},{"key":"BF03040906_CR6","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1006\/bbrc.2000.3497","volume":"276","author":"K Murao","year":"2000","unstructured":"Murao K, Ohyama T, Imachi H, Ishida T, Cao WM, Namihira H, et al (2000) TNF-alpha stimulation of MCP-1 expression is mediated by the Akt\/PKB signal transduction pathway in vascular endothelial cells. Biochem Biophys Res Commun 276: 791\u2013796","journal-title":"Biochem Biophys Res Commun"},{"key":"BF03040906_CR7","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/jlb.65.5.671","volume":"65","author":"S Yamashiro","year":"1999","unstructured":"Yamashiro S, Kamohara H, Yoshimura T (1999) MCP-1 is selectively expressed in the late phase by cytokine-stimulated human neutrophils: TNF-alpha plays a role in maximal MCP-1 mRNA expression. J Leukoc Biol 65: 671\u2013679","journal-title":"J Leukoc Biol"},{"key":"BF03040906_CR8","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1172\/JCI119662","volume":"100","author":"DR Ralston","year":"1997","unstructured":"Ralston DR, Marsh CB, Lowe MP, Wewers MD (1997) Antineutrophil cytoplasmic antibodies induce monocyte IL-8 release. J Clin Invest 100: 1416\u20131424","journal-title":"J Clin Invest"},{"key":"BF03040906_CR9","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/art.1780361206","volume":"36","author":"MJ Elliott","year":"1993","unstructured":"Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 36: 1681\u20131690","journal-title":"Arthritis Rheum"},{"key":"BF03040906_CR10","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/rheumatology\/34.4.334","volume":"34","author":"EC Rankin","year":"1995","unstructured":"Rankin EC, Choy EH, Kassimos D, Kingsley GH, Sopwith AM, Isenberg DA, et al (1995) The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 34: 334\u2013342","journal-title":"Br J Rheumatol"},{"key":"BF03040906_CR11","first-page":"680","volume":"30","author":"R Rau","year":"2003","unstructured":"Rau R, Sander O, van Riel P, van de Putte L, Hasler F, Zaug M, et al (2003) Intravenous human recombinant tumour necrosis factor recepter p55-Felg61 fusion protein RO45-2081 (Lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis. J Rheumatol 30: 680\u2013690","journal-title":"J Rheumatol"},{"key":"BF03040906_CR12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199707173370301","volume":"337","author":"LW Moreland","year":"1997","unstructured":"Moreland LW, Baumgartner SW, Schiff M, Tindall EA, Fleishmann RM, Weaver AL, et al (1997) Treatment of active, refractory rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p 75) Fe fusion protein (TNFR: Fe-EnbrelTM). N Engl J Med 337: 141\u2013147","journal-title":"N Engl J Med"},{"key":"BF03040906_CR13","first-page":"1849","volume":"23","author":"LW Moreland","year":"1996","unstructured":"Moreland LW, Margolies G, Heck LW Jr, Saway A, Blosch C, Hanna R, Koopman WJ (1996) Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 23: 1849\u20131855","journal-title":"J Rheumatol"},{"key":"BF03040906_CR14","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1136\/ard.58.2008.i70","volume":"58","author":"J Kempeni","year":"1999","unstructured":"Kempeni J (1999) Preliminary results of early clinical trials with the fully human anti-TNF monoclonal antibody D2E7. Ann Rheum Dis 58: 170\u2013172","journal-title":"Ann Rheum Dis"},{"key":"BF03040906_CR15","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1055\/s-2002-34065","volume":"127","author":"P Lamprecht","year":"2002","unstructured":"Lamprecht P, Arbach O, Voswinkel J, Lilienthal T, N\u00f6lle B, Heller M, et al (2002) Induction of remission with infliximab in therapy-refractory Wegener\u2019s granulomatosis \u2014 follow up of six patients. Dtsch Med Wochenschr 127: 1876\u20131880","journal-title":"Dtsch Med Wochenschr"},{"key":"BF03040906_CR16","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/rheumatology\/41.11.1303","volume":"41","author":"P Lamprecht","year":"2002","unstructured":"Lamprecht P, Voswinkel J, Lilienthal T, Nolle B, Heller M, Gross WL, et al (2002) Effectiveness of TNF-\u03b1 blockade with infliximab in refractory Wegener\u2019s granulomatosis. Rheumatol 41: 1303\u20131307","journal-title":"Rheumatol"},{"key":"BF03040906_CR17","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/rheumatology\/41.10.1126","volume":"41","author":"P Bartolucci","year":"2002","unstructured":"Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P, Le Hello C, et al (2002) Efficacy of the anti-TNF-\u03b1 antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatol 41: 1126\u20131132","journal-title":"Rheumatol"},{"key":"BF03040906_CR18","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/01.ASN.0000114554.67106.28","volume":"15","author":"A Booth","year":"2004","unstructured":"Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J, et al (2004) Prospective study of TNF-\u03b1 blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 15: 717\u2013721","journal-title":"J Am Soc Nephrol"},{"key":"BF03040906_CR19","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1002\/art.11075","volume":"48","author":"The Wegener\u2019s Granulomatosis Etanercept Trial Research Group","year":"2003","unstructured":"The Wegener\u2019s Granulomatosis Etanercept Trial Research Group (2003) Limited versus severe Wegener\u2019s granulomatosis. Arthritis Rheum 48: 2299\u20132309","journal-title":"Arthritis Rheum"},{"key":"BF03040906_CR20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s10067-002-0654-5","volume":"22","author":"M Debandt","year":"2003","unstructured":"Debandt M, Vittecoq O, Descamps V, Le Loet X, Meyer O (2003) Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol 22: 56\u201361","journal-title":"Clin Rheumatol"},{"key":"BF03040906_CR21","first-page":"2287","volume":"30","author":"SJ Jarrett","year":"2003","unstructured":"Jarrett SJ, Cunnane G, Conaghan PG, Bingham SJ, Buch MH, et al (2003) Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol 30: 2287\u20132291","journal-title":"J Rheumatol"},{"key":"BF03040906_CR22","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","volume":"44","author":"N Mohan","year":"2001","unstructured":"Mohan N, Edwards ET, Cupps TR, Oliviero PJ, Sandberg G, Crayton H, et al (2001) Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 44: 2862\u20132869","journal-title":"Arthritis Rheum"},{"key":"BF03040906_CR23","first-page":"1004","volume":"114","author":"E Cauza","year":"2002","unstructured":"Cauza E, Cauza K, Hanusch-Enserer U, Etemad M, Dunky A, Kostner K (2002) Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. Wien Klin Wochenschr 114: 1004\u20131007","journal-title":"Wien Klin Wochenschr"}],"container-title":["Wiener Klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03040906.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03040906\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03040906","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T03:37:37Z","timestamp":1684985857000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03040906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":23,"journal-issue":{"issue":"9-10","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["BF03040906"],"URL":"https:\/\/doi.org\/10.1007\/bf03040906","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,5]]}}}